Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality in
China. This study aimed to develop a hyaluronic acid (HA) decorated, pH sensitive lipid …

Core–shell type lipid–polymer hybrid nanoparticles (CSLPHNPs) have emerged as a
multifunctional drug delivery platform. The delivery system combines mechanical …

Special targeted therapy like endothelial growth factor receptor (EGFR) targeted therapy is
available for the treatment of advanced non-small cell lung cancer (NSCLC). Biodegradable …

Background Aim of this study was to prepare the hyaluronic acid and human serum albumin
modified erlotinib nanoparticles (ERT-HSA-HA NPs) delivery system by a precipitation …

In this study, a core-shell type polypeptide-based lipid nanocapsule was developed to
enhance anticancer efficacy of erlotinib in non-small cell lung cancers. Mean particle size of …

The rate of lung cancer in tuberculosis (TB) patients is 7 to 30% higher than that in healthy
individuals. Conventional chemotherapy of lung cancer shows limited efficiency due to poor …

Non-small cell lung cancer (NSCLC) patients with sensitizing mutations in the exons 18–21
of the epithelial growth factor receptor (EGFR) gene show increased kinase activity of EGFR …

Purpose Non-small cell lung cancer (NSCLC) accounts for the majority of lung cancer. Lipid–
polymer hybrid nanoparticles (LPNs) combine the advantages of both polymeric …

Purpose Erlotinib (ETB) is a well-established therapeutic for non-small-cell lung cancer
(NSCLC). To overcome drug resistance and severe toxicities in the clinical application …

Erlotinib-based EGFR targeted therapy has proven significant clinical improvement against
non-small cell lung cancer (NSCLC). However, the anticancer activity of Erlotinib (Ertb) is …